{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"1860","value":"232"},{"groupId":"OG001","lowerLimit":"89.7","upperLimit":"89.7","value":"89.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Tlast CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"888","value":"48.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Tlast NR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.0","upperLimit":"1460","value":"220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Tlast Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"1860","value":"179"},{"groupId":"OG001","lowerLimit":"89.7","upperLimit":"89.7","value":"89.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Tlast All Participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Persistence is defined as the time corresponding to last quantifiable transgene level in peripheral blood (Tlast), reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment.","dispersionType":"Full Range","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"MEDIAN","populationDescription":"PAS: The PAS consisted of patients in the FAS who had at least one sample providing evaluable cellular kinetic data for tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Persistence of Tisagenlecleucel (CTL019) in Blood, Bone Marrow and CSF if Available, by qPCR, by Day 28 Response by IRC","type":"SECONDARY","unitOfMeasure":"days"}